Bill > HR1922

This bill amends the Social Security Act to modify the Part D manufacturer discount program under Medicare by creating an exemption for certain orally administered drugs. Specifically, the bill would exclude from the discount program any orally administered drugs that: (1) have received a new drug application approval from the Food and Drug Administration under section 505 of the Federal Food, Drug, and Cosmetic Act, and (2) have been granted a narrow exception by the Centers for Medicare & Medicaid Services (CMS) that allows the drug to be reclassified as a noninnovator multiple source drug under the Medicaid drug rebate program. In plain language, this means certain newly approved prescription drugs taken by mouth would be excluded from Medicare's manufacturer discount requirements, potentially helping pharmaceutical companies maintain higher pricing for these specific medications. The bill's name, "Ensuring Access to Essential Drugs Act," suggests the intent is to support the continued development and availability of innovative oral medications by providing some financial protections for drug manufacturers.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/1922/all-info